Dr. Hahn leads the strategic and operational activities of Dana-Farber. He collaborates with other executives to reach more patients and communities, advance cancer research, and deliver outstanding patient-centered care. Most recently, Dr. Hahn played a leading role in Dana-Farber’s efforts to develop its future collaboration with Boston-based Beth Israel Deaconess Medical Center and the building of Dana-Farber’s proposed dedicated, adult inpatient oncology hospital. He has helped articulate and operationalize the ways in which a dedicated cancer hospital will improve care, advance access and equity, and lower costs. Dr. Hahn previously served as Dana-Farber’s chief scientific officer, leading the institute’s research enterprise and scientific mission. A renowned scientist himself, Dr. Hahn has made numerous discoveries that have informed our current molecular understanding of cancer. Dr. Hahn has been elected to the Association of American Physicians and the National Academy of Medicine. He is an institute member of the Broad Institute of MIT and Harvard and previously served as the president of the American Society for Clinical Investigation.
